- In November 2024, Sigma-Aldrich has announced the winners of its Emerging Biotech Grant Program, which supports innovative biotech startups and researchers. The program aims to foster the development of groundbreaking technologies in life sciences. Winners receive funding, resources, and mentorship to accelerate their research and product development, contributing to advancements in biotechnology
- In September 2024, Sigma-Aldrich has introduced the **Mobius™ ADC** (antibody-drug conjugate) platform, designed to streamline the development and manufacturing of biologics. This advanced platform offers a comprehensive solution for the efficient production of ADCs, enabling faster, more scalable, and cost-effective creation of targeted therapies, enhancing the development of innovative cancer treatments
- In December 2024, Thermo Fisher Scientific has launched CTS Detachable Dynabeads CD4 and CTS Detachable Dynabeads CD8 to support cell therapy development and production. These innovative tools enhance T cell isolation and expansion processes, improving the efficiency and scalability of cell therapies, offering new opportunities for advanced immunotherapies and personalized treatments
- In October 2024, Thermo Fisher Scientific highlighted its expanded biopharma services at CPhI Milan 2024, showcasing innovations designed to support the development and production of complex biologics and cell therapies. These advancements focus on improving the scalability, efficiency, and speed of biopharmaceutical manufacturing, underscoring Thermo Fisher's commitment to accelerating biopharma solutions
